Gilead files hep B therapy for FDA approval; Intellia launches gene editing subsidiary;

@FierceBiotech: Juno buys into sequencing; Moderna cozies up to Big Pharma; and more from . Article | Follow @FierceBiotech

@JohnCFierce: Sounds right. Deal fest in San Francisco while  takes an ugly 5% drop. Bon chance to you stock guys; off to a rough start at . | Follow @JohnCFierce

@DamianFierce: warm memories from last year's jp morgan when, after a full day of meetings, I found this on the back of my collar. More | Follow @DamianFierce

> Gilead Sciences ($GILD) filed its investigational tenofovir alafenamide for FDA approval in hepatitis B. News

> Moderna Therapeutics secured a $20 million grant from the Bill & Melinda Gates Foundation to advance its HIV candidate. More

> Intellia Therapeutics launched a new division focused on gene editing technology. Release

Medical Device News

@FierceMedDev: Medtronic to build Chinese facility for the manufacture of advanced diabetes devices. Article | Follow @FierceMedDev

@EmilyWFierce: Congressional reps urge the NIH to 'march in' on rising drug prices. FiercePharma story | Follow @EmilyWFierce

> JPM: Illumina's genomic ambitions fueled by new sequencing tools and technology. Story

> Boston Scientific launches disposable digital urinary tract endoscope. Article

> JPM: Medtronic aims for double-digit returns with more buybacks, faster dividends and debt paydown. More

Pharma News

@FiercePharma: BioAtla scores $45M investment for CAB development. FiercePharmaAsia story | Follow @FiercePharma

@CarlyHFierce: ICYMI: U.K. investor Woodford calls again for breakup of 'complicated' GSK. Article | Follow @CarlyHFierce

> Celgene ends horse race for Hugin's successor, tapping Mark Alles as new CEO. Story

> Now focused on integrating Allergan generics, Teva eyes 'much larger' specialty buy in 2017. Article

Drug Delivery News

> Australia's Elastagen receives $9M to deploy its human protein formulation to aesthetics and tissue repair. News

> Back-of-the-eye delivery outfit Clearside files for $58 million IPO. Story

> One microcapsule could combine two drug ingredients when triggered at tumor site. More

> JPM: Halozyme to focus on its internal pancreatic cancer candidate in 2016. Report

> Xeris raises $41M to develop diabetes injection pen for glucagon administration. Article

Pharma Manufacturing News

> BD exiting sterile injectables biz, selling plant and portfolio to Fresenius Kabi. More

> Consent decree issued against recalcitrant compounder. Item

> Perrigo, already recalling Zyrtec copy, now recalling knockoff of Mucinex for children. Report

> FDA warning letter tells Cadila to resolve problems with warfarin production. Story

> European regulators sanction Chinese company for plant flaws. Article

Pharma Asia News

> BioAtla scores $45M investment for CAB development. More

> Japan's Takeda and enGene in GI therapy development pact. Item

> Glenmark's BEAT platform helps develop new cancer molecule. Article

> Amgen sues South Korea's Samsung Bioepis over Enbrel biosimilar. Report

> Singapore's NRF unveils 5-year, $13B research budget. Story

Suggested Articles

The data, from two patients with severe blood disorders, are "promising” for what could be a one-and-done treatment, Cantor Fitzgerald analysts wrote.

The fund will back pharma companies as well as developers of medtech products and providers of outsourced services.

The money will fund work to develop polymers in multiple indications and an associated U.S. expansion.